

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6101861

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEVEN HARTMAN	05/09/2019
MICHELLE LOBEL	05/09/2019
MATTHEW P. ROBBEN	05/10/2019
KENNETH L. DRETCHEN	05/09/2019
MICHAEL MESA	05/12/2019
RECEIVING PARTY DATA	
Name:	BRYN PHARMA, LLC
Street Address:	7101 MILLSTONE RIDGE COURT
City:	RALEIGH
State/Country:	NORTH CAROLINA
Postal Code:	27614
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16864183
CORRESPONDENCE DATA	
Fax Number:	(269)337-7860
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2693377838
Email:	patents@honigman.com
Correspondent Name:	ANDREW N. WEBER
Address Line 1:	650 TRADE CENTRE WAY
Address Line 2:	SUITE 200
Address Line 4:	KALAMAZOO, MICHIGAN 49002-0402
ATTORNEY DOCKET NUMBER:	267864-465263
NAME OF SUBMITTER:	ANDREW N. WEBER
SIGNATURE:	/Andrew N. Weber/
DATE SIGNED:	05/12/2020
Total Attachments: 6	

source=267864_465263_Executed_Assignment#page1.tif
source=267864_465263_Executed_Assignment#page2.tif
source=267864_465263_Executed_Assignment#page3.tif
source=267864_465263_Executed_Assignment#page4.tif
source=267864_465263_Executed_Assignment#page5.tif
source=267864_465263_Executed_Assignment#page6.tif

PATENT ASSIGNMENT

Docket Number 53418-702.204

WHEREAS, the undersigned:

1. Steven Hartman
Beverly Hills, CA (US)
2. Michelle Lobel
Beverly Hills, CA (US)
3. Matthew P Robben
Pittsford, NY (US)
4. Kenneth L. Dretchen
Gaithersburg, MD (US)
5. Michael Mesa
Boyd's, MD (US)

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

EPINEPHRINE SPRAY FORMULATIONS

- ☐ for which a United States patent application is executed on even date herewith;
- ☐ for which application serial number 16/355,525 was filed on March 15, 2019 in the United States Patent and Trademark Office;
- ☐ for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
- ☐ for which application serial number _____ was filed on _____ in the _____ Patent Office;
- ☐ for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____; or
- ☐ for which a PCT application will be filed on or before [insert 12-month date] in the [] Receiving Office of the Patent Cooperation Treaty

which will claim priority to [_____].

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Bryn Pharma, LLC, a corporation incorporated in the State of Delaware, having a place of business at 7101 Millstone Ridge Court, Raleigh, NC 27614 (US), (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).



2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.


3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT		Docket Number 53418-702.204	
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			
Date: <u>5/9/15</u>	<u></u> Steven Hartman	Date: _____	_____
Date: _____	Matthew P Robben	Date: _____	Michelle Lobel
Date: _____	Michael Mesa	Date: _____	Kenneth L. Dretchen
RECEIVED AND AGREED TO BY ASSIGNEE: Bryn Pharma, LLC			
Date: <u>5/13/15</u>	Signature: <u></u> Name: Steven Hartman Title: Co-Founder		

PATENT ASSIGNMENT		Docket Number 53418-702.204	
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			
Date: _____	_____ Steven Hartman	Date: <u>5/9/19</u>	<u></u> Michelle Lobel
Date: _____	_____ Matthew P Robben	Date: _____	_____ Kenneth L. Dretchen
Date: _____	_____ Michael Mesa		
RECEIVED AND AGREED TO BY ASSIGNEE: Bryn Pharma, LLC			
Date: _____	Signature: _____ Name: Steven Hartman Title: Co-Founder		

PATENT ASSIGNMENT

Docket Number 53418-702.204

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____

Steven Hartman

Date: _____

Michelle Lobel

Date: 10 May 2019

Matthew P Robben

Date: _____

Kenneth L. Dretchen

Date: _____

Michael Mesa

RECEIVED AND AGREED TO BY ASSIGNEE: Bryn Pharma, LLC

Date: _____

Signature: _____


Name: Steven Hartman

Title: Co-Founder

PATENT ASSIGNMENT

Docket Number 53418-702.204

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.

Date: _____	Steven Hartman	Date: _____	Michelle Lobel
Date: _____	Matthew P Robben	Date: 5/9/17	
Date: _____	Michael Mesa		Kenneth L. Dretchen


RECEIVED AND AGREED TO BY ASSIGNEE: Bryn Pharma, LLC

Date: _____	Signature: _____
	Name: Steven Hartman
	Title: Co-Founder

PATENT ASSIGNMENT

Docket Number 53418-702.204

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.

Date: _____	_____	Date: _____	_____
	Steven Hartman		Michelle Lobel
Date: _____	_____	Date: _____	_____
	Matthew P Robben		Kenneth L. Dretchen
Date: <u>5/12/14</u>	 Michael Mesa		

RECEIVED AND AGREED TO BY ASSIGNEE: Bryn Pharma, LLC

Date: _____ Signature: _____
 Name: Steven Hartman
 Title: Co-Founder